Following a tumultuous time period involving a near-empty pipeline, multiple drug failures and a plummeting share price, the management of Lundbeck sees light at the end of the tunnel in its core area for central nervous system (CNS) diseases, which may have the potential to create a new era for the Danish pharmaceutical company.
"This is a unique time for us within CNS. Investments are being made like never before, and last year alone USD 11.5bn was invested. That's almost twice as much as the year before," says Lundbeck Executive Vice President and Chief Business Officer Keld Flintholm Jørgensen.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.